top stories

Jazz CEO Bruce Cozadd cam­paigned for 6 months to buy GW Phar­ma. A 90% pre­mi­um sealed the deal — along with $17.6M in ‘re­ten­tion’ in­cen­tives

2 days ago
Deals

Pfiz­er's trou­ble-prone McPher­son plant — now ramp­ing up vac­cine sup­plies — was cit­ed for con­tin­u­ing vi­o­la­tions in ...

2 days ago
Manufacturing

Af­ter three years of courtship (and turn­downs), Mer­ck pounced on the first glance of clin­i­cal da­ta in $1.85B Pan­dion ...

2 days ago
Deals

Latest

Most read

The top 100 bio­phar­ma VCs, Bob Brad­way places $2B bet in can­cer, gene edit­ing pi­o­neer's new big idea, and more

Yesterday
Weekly

Covid-19 roundup: RE­COV­ERY tri­al halts re­cruit­ment for colchicine study af­ter find­ing ‘no con­vinc­ing ev­i­dence’; ...

2 days ago
Coronavirus

Seagen warns in­vestors against TRC Cap­i­tal’s lat­est 'mi­ni-ten­der of­fer'; BeiGene goes af­ter a new in­di­ca­tion for ...

2 days ago
News Briefing

UP­DAT­ED: Not 3 weeks af­ter tak­ing Hu­ma­cyte pub­lic, Ra­jiv Shuk­la launch­es an­oth­er blank check com­pa­ny

2 days ago
Financing
see latest stream
People

How does Paul Hud­son's $13.5M comp pack­age stack up against oth­er CEOs? He's in the 'first quar­tile'

2 days ago

An Ar­ray co-founder re-emerges as CEO of a small aca­d­e­m­ic spin­out, look­ing to re­make an old class of can­cer drugs

2 days ago

With dust set­tled on ac­tivist at­tack, Lau­rence Coop­er leaves Zio­pharm to a new board

Last week
Financing

With $117M in fresh cash, Amu­nix paves path to the clin­ic for 'u­ni­ver­sal mask' pro­drug on the hunt for HER2 tu­mors

3 days ago

Black­Rock push­es Ex­sci­en­tia Se­ries C to $100M as AI biotech boom con­tin­ues

3 days ago

Pe­ter Thiel-backed psy­che­delics play­er ATAI pulls in an­oth­er nine-fig­ure raise. But they're not ready to talk IPO — ...

4 days ago
Startups

Khosla joins bet on un­con­ven­tion­al start­up look­ing to send drug de­liv­er­ing ro­bots in­to the brain

4 days ago

Sean Nolan gath­ers AveX­is alum­ni to launch an­oth­er biotech. Is it an­oth­er race-to-IPO?

Last week

Flag­ship up­start Cel­lar­i­ty gath­ers $123M to fi­nance its ex­plo­ration of cell be­hav­ior, blaz­ing a new path to build­ing ...

Last week
Deals

UP­DAT­ED: Am­gen snaps up can­cer drug play­er Five Prime, adding PhI­II-ready FGFR2b drug in $2B M&A play

3 days ago

The 2021 top 100 bio­phar­ma in­vestors: As the pan­dem­ic hit and IPOs boomed, VCs swung in­to ac­tion like nev­er be­fore

4 days ago

Thank you, next: Take­da hands Ovid $196M cash to rein back in Phase III-ready seizure drug, re­viv­ing bat­tered stock

4 days ago

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News

Premium storiesSee all

David Liu has a new big idea: pro­teome edit­ing. It could one day shred tau, RAS and some of the worst dis­ease-caus­ing ...

3 days ago
Discovery
In Focus

Roivant par­lays a $450M chunk of eq­ui­ty in biotech buy­out, grab­bing a com­pu­ta­tion­al group to dri­ve dis­cov­ery work

Last week
Deals

Bio­phar­ma's suc­cess rate in bring­ing drugs to mar­ket has long been abysmal. Can new tools help rewrite that trou­bled ...

Last week
In Focus

The $1M IPO bonus, de­cent pay and a nice eq­ui­ty stake to mark the up­side: How does Mark McKen­na's comp pack­age stack ...

Last week
Financing
Bioregnum

Don't missSee all

In the lat­est big in­vest­ment in gene ther­a­py man­u­fac­tur­ing, Bio­gen com­mits $200M to a ma­jor new fa­cil­i­ty in NC

3 days ago
Cell/Gene Tx
Manufacturing

Eli Lil­ly claims a TKO in its long-run­ning ti­tle fight with No­vo Nordisk for the block­buster di­a­betes mar­ket — but ...

3 days ago
R&D

GSK, Vir's hopes for a Covid-19 an­ti­body fall flat in NIH 'mas­ter pro­to­col' with no ben­e­fit in hos­pi­tal­ized pa­tients

4 days ago
R&D
Coronavirus

As Brain­Storm con­tin­ues to tout ‘clear sig­nal’ on ALS drug, the FDA of­fers a rare pub­lic slap­down on the da­ta

4 days ago
Regulatory

Endpoints Standouts

2020’s NDA list is packed with com­mer­cial firsts — from his­toric to hap­haz­ard. Have we reached a tip­ping point?

2 months ago
Special

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women blaz­ing trails in bio­phar­ma R&D — Covid-19 and be­yond

2 months ago
People
In Focus

The End­points 11: Here are some of the most promis­ing star­tups in biotech. And Covid-19 is­n't go­ing to stop them

5 months ago
Startups
In Focus

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

11 months ago
People
Special

Peer review See all

Mar
5

Genen­tech gains clin­i­cal de­vel­op­ment ex­ec by ap­point­ing Lil­li Petruzzel­li; Paul Sekhri caps event­ful week, nam­ing ...

Feb
26

Mark Mal­lon charts post-Iron­wood course by tak­ing CEO job at NeoGe­nomics; Glax­o­SmithK­line vet Feng Ren joins In­sil­i­co ...

Feb
19

Hen­ry Skin­ner buys time in the fight against an­timi­cro­bial re­sis­tance; Ver­tex's Michael Pari­ni be­comes pres­i­dent and ...

Feb
12

Ex-Vi­vid­ion chief Diego Mi­ralles finds 'dream team' at stealthy Flag­ship port­fo­lio com­pa­ny; Astel­las looks in­ward to ...

Feb
5

For­mer Glax­o­SmithK­line CEO An­drew Wit­ty takes the helm at Unit­ed­Health; Af­ter more than a decade, Daniel Chung is ...

Manufacturing channel feed

2 days ago

Covid vac­cine roundup: US vac­cine sup­plies grow, but ex­perts warn of po­ten­tial hic­cups in sup­ply chain; Emer­gent touts grow­ing Covid vac­cine ca­pac­i­ty

The Biden ad­min­is­tra­tion has been rais­ing hopes in the US that there will be am­ple vac­cine sup­plies to in­oc­u­late more than 250 mil­lion Amer­i­can adults by May. There have been new deals with ...

READ MORE

Ab­b­Vie of­floads UK site for $119M in sale to Chi­nese cell and gene ther­a­py play­er Phar­maron

2 days ago
Outsourcing
Cell/Gene Tx

No­var­tis pairs up with Cure­Vac to help dri­ve Covid-19 shot pro­duc­tion but may miss the show in the US, EU

3 days ago
Coronavirus
latest in Manufacturing

UP­DAT­ED: Swiss CD­MO Celonic finds a home at No­var­tis' Stein hub, plans to add 250 new jobs cen­tered on next-gen drugs

4 days ago
Outsourcing
Cell/Gene Tx

With stars aligned and cash in re­serve, Bob Nelsen's Re­silience plans a makeover at 2 new fa­cil­i­ty ad­di­tions to its drug man­u­fac­tur­ing up­start

5 days ago

Af­ter bail­ing on Covid-19 vac­cines, Mer­ck will team up with J&J to pro­duce its shot as part of un­usu­al Big Phar­ma pact

5 days ago
Coronavirus

A 'love sto­ry': WuXi AppTec wraps UK-based CRO in­to its cell and gene ther­a­py unit

5 days ago
Deals
Outsourcing

Avid Bioser­vices, with re­cent IPO and Covid-19 part­ner­ship in hand, launch­es 2nd phase of fa­cil­i­ty ex­pan­sion

Last week
Outsourcing
see latest stories

Pharma channel feed

2 days ago

Fo­cus­ing on the bright side, FDA OKs Roche's Actem­ra for rare lung dis­ease de­spite PhI­II flop

Actem­ra’s fail­ure to hit the pri­ma­ry end­point in a Phase III study didn’t stop the FDA from grant­i­ng Roche pri­or­i­ty re­view. And it’s cer­tain­ly not stand­ing in the way of a sixth ...

READ MORE

Lat­est Mass­Bio re­port shows just how much bio­phar­ma's biggest sec­tor boomed in 2020

3 days ago

Amid back of­fice con­sol­i­da­tion, Gilead ax­es 179 jobs in Cal­i­for­nia

3 days ago
latest in Pharma

UP­DAT­ED: Mer­ck pulls Keytru­da in SCLC af­ter ac­cel­er­at­ed nod. Is the FDA get­ting tough on drug­mak­ers that don't hit their marks?

6 days ago
Regulatory

An­gling Pfiz­er, As­traZeneca jumps in­to com­mer­cial PD-(L)1 fight in Chi­na

6 days ago
Deals
China

Pas­cal So­ri­ot cash­es in As­traZeneca’s chips on Mod­er­na for $1.2B cash in­jec­tion

6 days ago

Why not? Sarep­ta’s third Duchenne MD drug sails to ac­cel­er­at­ed ap­proval

Last week
Regulatory

S&P ex­pects steady ero­sion in Big Phar­ma's cred­it pro­file in 2021 as new M&A deals roll in — but don't un­der­es­ti­mate their un­der­ly­ing strength

Last week
see latest stories

R&D channel feed

4 days ago

Eli Lil­ly claims suc­cess in a new JAK in­di­ca­tion: hair loss

Over the last decade, drug­mak­ers have proven JAK in­hibitors can treat a smat­ter­ing of im­mune-re­lat­ed dis­eases rang­ing from rheuma­toid arthri­tis to Covid-19. Now Eli Lil­ly has pulled out a ...

READ MORE

Apel­lis joins the grow­ing num­ber of bio­phar­mas scrap­ping a failed Covid-19 pro­gram af­ter an ear­ly flop

3 days ago
Coronavirus

Kro­nos seals pact with reg­u­la­tors to hunt AML with pre­vi­ous­ly off-lim­its bio­mark­er end­point

3 days ago
latest in R&D

One of Are­na's top drugs flops in a PhI­Ib study for IBS pain. But re­searchers tease out a pos­si­ble path for­ward as CEO ex­plores 's­trate­gic op­tion­s'

4 days ago

'N­ev­er been more ur­gent:' Scynex­is looks to tack­le su­per­bug cri­sis with late-stage read­out for an­ti­fun­gal hope­ful

5 days ago

A spot­light schiz­o­phre­nia drug in Neu­ro­crine's $2B Take­da deal flunks its first ma­jor test. But it's not giv­ing up yet

5 days ago

Mer­ck KGaA ear­marks $855M for De­bio­phar­m's pro­grammed cell death pro­mot­ing drug in glob­al li­cens­ing deal

6 days ago
Deals

Roche and Genen­tech re­searchers plot $53M dis­cov­ery quest aimed at spark­ing a 'Holy moly' piv­ot in neu­ro R&D

Last week
Deals
see latest stories

Regulatory channel feed

3 days ago

Pfiz­er's Xalko­ri fol­low-up, which smoked the old­er drug in 1st-line pa­tients, scores dou­ble win at the FDA

De­spite be­ing the first to mar­ket in ALK-pos­i­tive non-small cell lung can­cer, Pfiz­er's Xalko­ri lan­guished on the shelf as oth­er com­peti­tors out­paced it. Now, af­ter Pfiz­er's fol­low-up drug ...

READ MORE

Unit­ed ax­es PAH pro­gram Trevyent, once bought for cheap in ac­qui­si­tion of a ri­val, af­ter FDA feed­back

4 days ago

Fi­bro­Gen shares skid low­er as a sur­prise ad­comm rais­es risks on roxa OK

5 days ago
latest in Regulatory

UP­DAT­ED: Biotech's shares rout­ed af­ter the FDA de­mands new tri­al, rais­es safe­ty and end­point is­sues in sur­prise CRL

6 days ago

Bridge­Bio spins gold out of an Alex­ion castoff, scor­ing an FDA ap­proval in rare me­tab­o­lism dis­or­der

6 days ago

UP­DAT­ED: Feds clear the road for J&J to start de­liv­er­ing mil­lions of dos­es of their Covid-19 vac­cine — but frets linger about run­ner-up sta­tus

Last week
Coronavirus

Biden is look­ing be­yond Wood­cock or Sharf­stein for FDA com­mis­sion­er — re­port

Last week
People

FDA re­view­ers en­dorse J&J sin­gle-dose shot, lay­ing path for 3rd US vac­cine

Last week
see latest stories